DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $9,585,704 | +28.1% | 324,829 | 0.0% | 0.38% | +31.6% |
| Q1 2023 | $7,484,060 | -1.2% | 324,829 | +19.2% | 0.28% | -0.3% |
| Q4 2022 | $7,578,781 | +11.0% | 272,520 | +22.5% | 0.29% | +2.5% |
| Q3 2022 | $6,826,000 | +4.3% | 222,420 | 0.0% | 0.28% | +8.6% |
| Q2 2022 | $6,546,000 | -8.5% | 222,420 | 0.0% | 0.26% | +2.4% |
| Q1 2022 | $7,155,000 | -27.9% | 222,420 | 0.0% | 0.25% | -21.3% |
| Q4 2021 | $9,920,000 | -11.6% | 222,420 | 0.0% | 0.32% | -11.6% |
| Q3 2021 | $11,221,000 | -4.7% | 222,420 | +48.2% | 0.36% | -5.7% |
| Q2 2021 | $11,773,000 | +37.4% | 150,086 | 0.0% | 0.38% | +29.8% |
| Q1 2021 | $8,570,000 | +41.4% | 150,086 | +107.5% | 0.30% | +38.5% |
| Q4 2020 | $6,059,000 | +1246.4% | 72,333 | +273.4% | 0.21% | +1083.3% |
| Q1 2019 | $450,000 | – | 19,372 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |